Small Molecules

26 Jun 2018 Selective AXL Inhibitor Bemcentinib Meets Pre-specified Efficacy Endpoint in Stage 1 of NSCLC Phase II Combination Trial With KEYTRUDA®
26 Jun 2018 ORYZON announces First Patients in the UK in ETHERAL: a Phase IIa clinical trial in Alzheimer’s Disease with ORY-2001
26 Jun 2018 FDA Grants Priority Review to Genentech’s Baloxavir Marboxil for the Treatment of Influenza
25 Jun 2018 Pfizer Announces Overall Survival Results from Phase 3 PALOMA-3 Trial of IBRANCE® (Palbociclib) in HR+, HER2- Metastatic Breast Cancer
25 Jun 2018 GW Pharmaceuticals plc and its U.S. Subsidiary Greenwich Biosciences Announce FDA Approval of EPIDIOLEX® (cannabidiol) oral solution – the First Plant-derived Cannabinoid Prescription Medicine
25 Jun 2018 CellCentric enters clinic with first-in-class p300/CBP inhibitor for late-stage prostate cancer
24 Jun 2018 Ironwood Presents Praliciguat Phase IIa Study Data Showing Positive Impact on Metabolic and Cardiovascular Clinical Endpoints at the American Diabetes Association’s 78th Scientific Sessions
24 Jun 2018 Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes
22 Jun 2018 Ironwood Pharmaceuticals Initiates Pivotal Phase III Program for IW-3718 in Persistent Gastroesophageal Reflux Disease
22 Jun 2018 Mezzion Pharma and NHLBI-Funded Pediatric Heart Network Complete Enrollment in a Pivotal Phase 3 Clinical Trial of Udenafil in Adolescents with Fontan Surgical Palliation - an Orphan Drug Indication
22 Jun 2018 Nanobiotix announces positive phase II/III topline data in soft tissue sarcoma with NBTXR3
21 Jun 2018 Servier and Taiho Announce Phase III Trial Data Demonstrates Significant Overall Survival Benefit of LONSURF® (trifluridine and tipiracil) in Patients with Metastatic Gastric Cancer
21 Jun 2018 Heron Announces Positive Topline Results from Phase 2b Clinical Studies of HTX-011 in Total Knee Arthroplasty and Breast Augmentation
21 Jun 2018 Incyte Announces REACH1 Pivotal Trial Meets Primary Endpoint of Overall Response Rate for Ruxolitinib (Jakafi®) in Steroid-Refractory Acute Graft-Versus-Host Disease
21 Jun 2018 Taiho Oncology Presents Data on Key Investigational Compound TAS-120 at ESMO 20th World Congress on Gastrointestinal Cancer 2018
21 Jun 2018 CStone enrolls first patient in Phase I study for MEK inhibitor CS3006 in Australia
21 Jun 2018 Aminex Therapeutics Initiates First Clinical Trial of Novel Immunotherapy AMXT 1501 + DFMO in Cancer Patients
21 Jun 2018 Reata Announces Initiation of a Phase 1 Trial of RTA 1701, a Selective, Oral Allosteric Inhibitor of RORγt
21 Jun 2018 Enrollment of first patient in Phase II clinical trial for Gaucher disease
20 Jun 2018 Idorsia initiates PRECISION - Phase 3 study with aprocitentan for resistant hypertension management
19 Jun 2018 Marinus Pharmaceuticals Initiates Pivotal Phase 3 Trial in Children with CDKL5 Deficiency Disorder
19 Jun 2018 Protagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting
19 Jun 2018 Updated Preliminary Data from SMA FIREFISH Program in Type 1 Babies Presented at the CureSMA Conference
19 Jun 2018 Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 European Hematology Association (EHA) Annual Meeting in Stockholm
19 Jun 2018 Idorsia is initiating REACT - Phase 3 registration study with clazosentan

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up